Compare Abeona Therapeutics Inc (ABEO) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MBS ETF — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while iShares MBS ETF trades at $93.17. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | MBB | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $96.91 |
52-Week Low | $4.17 | $92.72 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
MBB trades at $93.255 with a modest 0.36% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock has demonstrated consistent dividend payments with recent payouts of $0.34 per share. Institutional interest appears positive with Focus Financial Network increasing its stake by 13.8% during the latest reporting period.
The outlook remains cautious given the bearish technical signals, though steady dividend payments provide income stability. Key risks include market volatility and interest rate sensitivity. Investment opportunity lies in the consistent dividend yield and institutional accumulation, but requires monitoring of technical resistance levels around $93.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
